29.61 0.00 (0.00%)
After hours: 4:36PM EDT
|Bid||29.59 x 700|
|Ask||29.65 x 800|
|Day's Range||29.51 - 29.93|
|52 Week Range||19.67 - 29.93|
|PE Ratio (TTM)||52.97|
|Earnings Date||Oct 26, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.02|
MARLBOROUGH, Mass. , Oct. 23, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced key data that will be presented at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual ...
Political turmoil and the health policy related battle apart, majority of the MedTech stocks' bottom line is likely to be hurt in the third quarter on escalating costs induced by consecutive hurricanes and Mexico earthquakes.
BSX's EPS estimate for 3Q17 represents YoY (year-over-year) growth in the range of 9%–16%. In 2Q17, Boston Scientific registered EPS growth of 18.5% YoY.
Boston Scientific's (BSX) 3Q17 revenues are expected to come in at $2.21 billion, representing YoY (year-over-year) growth of ~4.8%.
BSX stock has been performing well recently, and investor confidence appears to have ridden on innovative product launches and strong 2Q17 results.
Although Boston Scientific's (BSX) recent $435-million acquisition of Symetis SA might drive its IC business, the company's full recovery post a primary product recall may however, take time.
CAMPBELL, Calif. , Oct. 16, 2017 /PRNewswire/ -- Shifamed LLC, a privately held medical device incubator, announced that Apama Medical, Inc., a Shifamed Portfolio Company, was acquired by Boston Scientific ...
With hundreds of workers missing after Hurricane Maria devastated the island, health-care and other firms turned to the airwaves.
Boston Scientific (BSX) is gaining traction on product launch and accretive acquisitions. Yet an unfavorable currency movement is a major dampener.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. Over the last one-month, outflows of investor capital in ETFs holding BSX totaled $6.94 billion.
A pacemaker for the brain can be used to treat symptoms of neurological disorders like Parkinson’s Disease.
MARLBOROUGH, Mass. , Oct. 4, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Desiree Ralls-Morrison as senior vice president, general counsel and corporate ...
Boston Scientific's (BSX) Apama Medical addition is expected to strengthen its suite of arrhythmia solutions under the Electrophysiology sub-segment.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. Over the last one-month, outflows of investor capital in ETFs holding BSX totaled $3.92 billion.
Boston Scientific Corporation (NYSE:BSX) is trading with a trailing P/E of 50.5x, which is higher than the industry average of 42.6x. While this makes BSX appear like a stock toRead More...
The deal represents a healthy return for venture-capital investors in the maker of atrial fibrillation treatment products.
MARLBOROUGH, Mass., Oct. 2, 2017 /PRNewswire/ -- Boston Scientific Corporation (BSX) today announced a definitive agreement to acquire Apama Medical Inc., a privately-held company that is developing the Apama Radiofrequency (RF) Balloon Catheter System for the treatment of atrial fibrillation (AF). AF, a common heart rhythm disorder estimated to affect more than 33 million people worldwide,1 is commonly treated with anti-arrhythmic drugs as well as cardiac ablation – the process of delivering energy to the areas of the heart muscle causing an abnormal rhythm. The standard of care in AF ablations is pulmonary vein isolation (PVI) – the application of energy to create lines of scar tissue around the pulmonary veins in the left atrium to block unwanted electrical signals that trigger AF.
MARLBOROUGH, Mass. , Oct. 2, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended ...
The PAS2 study, which is a post-approval clinical trial, was conducted at 27 sites across the United States and Canada.
According to the recommendations of 24 brokerage companies surveyed by Reuters, ~75% of the analysts provided a “buy” rating for BSX stock.